TEVA Q4 2022 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B-5.3% YoY

Gross Profit

$1.8B45.6% margin

Operating Income

-$855M-22.0% margin

Net Income

-$1.2B-31.4% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

+8.0%

Cash Flow

Operating Cash Flow

$973M

Free Cash Flow

$831M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$44.0B

Total Liabilities

$35.4B

Stockholders' Equity

$7.8B

Cash & Equivalents

$2.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$4.1B	-5.3%
Gross Profit	$1.8B	$2.0B	-13.7%
Operating Income	-$855M	$78M	-1196.2%
Net Income	-$1.2B	-$159M	-667.9%

Revenue Segments

Product

$3.3B85%

Distribution Service

$460M12%

Product and Service, Other

$54M1%

License

$50M1%

Geographic Segments

North America Segment

$2.0B55%

Europe Segment

$1.1B31%

International Markets

$482M13%